CPT codes

53867 CPT codes with hospital pricing data in the network.

• CPT 431T — Replacement Of Pulse Generator Of Neurostimulator System For Treatment Of Central Sleep Apnea (8 hospitals, — samples)
• CPT 431U — GLY RCPTR ALPHA1 IGG SRM/CSF (85 hospitals, — samples)
• CPT 43290 — EGD FLX TRNSORL DPLMNT BALO (571 hospitals, — samples)
• CPT 43291 — EGD FLX TRNSORL RMVL BALO (584 hospitals, — samples)
• CPT 432T — Repositioning Of Stimulating Lead Of Neurostimulator System For Treatment Of Central Sleep Apnea (8 hospitals, — samples)
• CPT 432U — KLHL11 ANTB SR/CSF ASY QUAL (85 hospitals, — samples)
• CPT 433T — Repositioning Of Sensing Lead Of Neurostimulator System For Treatment Of Central Sleep Apnea (8 hospitals, — samples)
• CPT 433U — ONC PRST8 5 DNA REG MRK PCR (85 hospitals, — samples)
• CPT 434T — Interrogation Evaluation Of Implanted Neurostimulator Pulse Generator System For Central Sleep Apnea (8 hospitals, — samples)
• CPT 434U — RX METAB ADVRS VRNT ALYS 25 (85 hospitals, — samples)
• CPT 435T — Programming Evaluation Of Implanted Neurostimulator Pulse Generator System For Central Sleep Apnea In One Session (8 hospitals, — samples)
• CPT 435U — ONC CHEMO RX CYTOX CSC 14 RX (85 hospitals, — samples)
• CPT 436T — Programming Evaluation Of Implanted Neurostimulator Pulse Generator System For Central Sleep Apnea During Sleep Study (9 hospitals, — samples)
• CPT 436U — ONC LNG PLSM ALYS 388 PRTN (85 hospitals, — samples)
• CPT 437T — IMPLTJ SYNTH RNFCMT ABDL WAL (85 hospitals, — samples)
• CPT 437U — PSYC ANXIETY DO MRNA 15 BMRK (85 hospitals, — samples)
• CPT 438U — RX METAB ADVRS VRNT ALYS 33 (85 hospitals, — samples)
• CPT 439T — MYOCRD CONTRAST PRFUJ ECHO (82 hospitals, — samples)
• CPT 439U — Cardiology (coronary heart disease [CHD]), DNA, analysis of 5 single-nucleotide polymorphisms (SNPs) (rs11716050 [LOC105376934], rs6560711 [WDR37], rs3735222 [SCIN/LOC107986769], rs6820447 [intergenic], and rs9638144 [ESYT2]) and 3 DNA methylation markers (85 hospitals, — samples)
• CPT 43U — TBRF B GRP ANTB 4 PRTN IGM (85 hospitals, — samples)
• CPT 440T — ABLTJ PERC UXTR/PERPH NRV (85 hospitals, — samples)
• CPT 440U — Cardiology (coronary heart disease [CHD]), DNA, analysis of 10 single-nucleotide polymorphisms (SNPs) (rs710987 [LINC010019], rs1333048 [CDKN2B-AS1], rs12129789 [KCND3], rs942317 [KTN1-AS1], rs1441433 [PPP3CA], rs2869675 [PREX1], rs4639796 [ZBTB41], rs437 (85 hospitals, — samples)
• CPT 441T — ABLTJ PERC LXTR/PERPH NRV (85 hospitals, — samples)
• CPT 441U — Infectious disease (bacterial, fungal, or viral infection), semiquantitative biomechanical assessment (via deformability cytometry), whole blood, with algorithmic analysis and result reported as an index (85 hospitals, — samples)
• CPT 442T — ABLTJ PERC PLEX/TRNCL NRV (84 hospitals, — samples)
• CPT 442U — Infectious disease (respiratory infection), Myxovirus resistance protein A (MxA) and C-reactive protein (CRP), fingerstick whole blood specimen, each biomarker reported as present or absent (85 hospitals, — samples)
• CPT 443T — R-T SPCTRL ALYS PRST8 TISS (85 hospitals, — samples)
• CPT 443U — Neurofilament light chain (NfL), ultra-sensitive immunoassay, serum or cerebrospinal fluid (85 hospitals, — samples)
• CPT 444T — 1ST PLMT DRUG ELUT OC INS (85 hospitals, — samples)
• CPT 444U — Oncology (solid organ neoplasia), targeted genomic sequence analysis panel of 361 genes, interrogation for gene fusions, translocations, or other rearrangements, using DNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue, report of clinically sig (85 hospitals, — samples)
• CPT 445T — SBSQT PLMT DRUG ELUT OC INS (85 hospitals, — samples)
• CPT 445U — β-amyloid (Abeta42) and phospho tau (181P) (pTau181), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology (85 hospitals, — samples)
• CPT 446T — INSJ IMPLTBL GLUCOSE SENSOR (84 hospitals, — samples)
• CPT 446U — Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 10 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic risk score for current disease activity (85 hospitals, — samples)
• CPT 447T — RMVL IMPLTBL GLUCOSE SENSOR (85 hospitals, — samples)
• CPT 447U — Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 11 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic prognostic risk score for developing a clinical flare (85 hospitals, — samples)
• CPT 448T — REMVL INSJ IMPLTBL GLUC SENS (85 hospitals, — samples)
• CPT 449T — INSJ AQUEOUS DRAIN DEV 1ST (85 hospitals, — samples)
• CPT 449U — Carrier screening for severe inherited conditions (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia), regardless of race or self-identified ancestry, genomic sequence analysis panel, (85 hospitals, — samples)
• CPT 44U — TBRF B GRP ANTB 4 PRTN IGG (85 hospitals, — samples)
• CPT 450T — INSJ AQUEOUS DRAIN DEV EACH (85 hospitals, — samples)
• CPT 450U — Oncology (multiple myeloma), liquid chromatography with tandem mass spectrometry (LC-MS/MS), monoclonal paraprotein sequencing analysis, serum, results reported as baseline presence or absence of detectable clonotypic peptides (85 hospitals, — samples)
• CPT 451U — Oncology (multiple myeloma), LC-MS/MS, peptide ion quantification, serum, results compared with baseline to determine monoclonal paraprotein abundance (85 hospitals, — samples)
• CPT 452U — Oncology (bladder), methylated PENK DNA detection by linear target enrichment-quantitative methylation-specific real-time PCR (LTE-qMSP), urine, reported as likelihood of bladder cancer (85 hospitals, — samples)
• CPT 453U — Oncology (colorectal cancer), cell-free DNA (cfDNA), methylation-based quantitative PCR assay (SEPTIN9, IKZF1, BCAT1, Septin9-2, VAV3, BCAN), plasma, reported as presence or absence of circulating tumor DNA (ctDNA) (85 hospitals, — samples)
• CPT 454U — Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping (85 hospitals, — samples)
• CPT 455U — Infectious agents (sexually transmitted infection), Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis, multiplex amplified probe technique, vaginal, endocervical, gynecological specimens, oropharyngeal swabs, rectal swabs, female or (85 hospitals, — samples)
• CPT 457U — Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 9 PFAS compounds by LC-MS/MS, plasma or serum, quantitative (85 hospitals, — samples)
• CPT 458U — Oncology (breast cancer), S100A8 and S100A9, by enzyme-linked immunosorbent assay (ELISA), tear fluid with age, algorithm reported as a risk score (85 hospitals, — samples)
• CPT 459U — β-amyloid (Abeta42) and total tau (tTau), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology (85 hospitals, — samples)